Skip to content

Integrating QSAR, molecular dynamics and MM-GBSA to re-rank natural product-derived DPP4 candidates from virtual screening.

Oct 2026 · SAR and QSAR in environmental research (Print) · pp. 1-31 · 0 citations · 65 references
Medicine

Abstract

Dipeptidyl peptidase-4 (DPP4) is a validated target for type 2 diabetes, and virtual screening of natural product libraries is a common route to new chemotypes. We asked whether a top docking rank survives independent scrutiny. From COCONUT, 85,600 compounds were filtered to 32,008 and docked against DPP4; 873 outscored the crystallographic ligand N7F (-10.01 kcal/mol), with Lig_771 first at -12.5 kcal/mol. Across four 300 ns simulations (two replicas per complex, 1.2 μs) Lig_771 stayed bound but never reproduced the gliptin recognition motif: the control held its salt bridges to Glu205 and Glu206 in over 93% of frames, whereas Lig_771 formed no persistent hydrogen bond to these residues and sampled two distinct poses. MM-GBSA gave -15.6 kcal/mol for Lig_771 against -23.9 for the control. A QSAR model built on 4327 measured DPP4 inhibitors (scaffold-based external R2 = 0.415; random split 0.669) predicted a pIC50 of 6.59 for Lig_771, below linagliptin (8.29), sitagliptin (7.39) and vildagliptin (6.96). None of the three analyses corroborated the docking ranking. The study is computational and does not establish DPP4 inhibition. Lig_771 occupies largely unexplored chemical space (maximum Tanimoto similarity 0.316) and merits testing, but selecting hits on docking score alone would have been misleading here.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.